KRYS — Krystal Biotech, Inc.
Is KRYS overbought or oversold? Here is the current MarketMoodz read.
Krystal Biotech, Inc. (KRYS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $297.90. The rating moved from Oversold to Neutral on November 14, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$297.90
- Last changeMoved from Oversold to Neutral on November 14, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
Krystal Biotech is a specialist gene-therapy company focused on dermatologic rare diseases with a concentrated pipeline and binary milestone-driven upside. Near-term prospects hinge on clinical/regulatory outcomes and the company’s ability to commercialize and obtain payer coverage; acquisition interest from larger specialty-focused pharma could provide strategic optionality. The current market environment is mildly risk-on and orderly, which may favor measured re-pricing around catalyst events, but limited public disclosure and the typical small‑cap biotech volatility create elevated execution and financing risk.
Key factors
- Narrow, high-value dermatology/rare disease commercial opportunity with differentiated gene-therapy platform
- Clinical and regulatory milestones drive binary upside; approval/launch execution critical for revenue realization
- Potential acquisition interest from large-cap pharma consolidating into specialty franchises increases strategic optionality
- Limited available public financial disclosures in the provided window and absence of recent EDGAR details increase near-term uncertainty
- Market tone is cautiously risk-on with limited volatility, which may support orderly re-pricing around news rather than panic selling
- Small-cap / biotech sector dynamics: high volatility, significant post-data moves, and sensitivity to payer/reimbursement developments
Risks
- Clinical or regulatory setbacks on core pipeline or label limitations that materially reduce addressable market
- Commercial execution risk: limited sales infrastructure and challenges securing payer coverage for high-cost therapies
- Cash runway and financing risk for continued development/launch if revenue ramp is slower than expected
- Competition from larger pharma with deeper commercial reach, including fast-follow biologics or alternative therapies
- High share-price volatility typical of single-product/small biotech names leading to large drawdowns on negative news
- Limited social sentiment and EDGAR signal availability in the reviewed window, creating information asymmetry for investors
See today's live rating, score and targets
Members see the live hourly rating for KRYS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.